-+ 0.00%
-+ 0.00%
-+ 0.00%

Zentalis Pharmaceuticals Announces Data Presented From Two Posters Regarding Preclinical Activity Of Azenosertib In Triple-Negative Breast Cancer At 2026 American Association For Cancer Research

Benzinga·04/17/2026 19:20:14
Listen to the news

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced data from two posters being presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, CA. The data show encouraging preclinical activity of azenosertib in triple-negative breast cancer (TNBC) and highlight the poor prognosis of Cyclin E1-positive ovarian cancer patients with currently available treatments in a real-world data analysis.